EPG Online Twitter 
EPG Online Blog 
Disease Knowledge Drug Updates
- Fostair 100/6 inhalation solution
- Epanutin capsules 25, 50 and 100mg
- Eprex 2000, 4000 and 10000 IU/ml solution for injection in pre-filled syringe
- FemSeven Conti
- Epanutin 300mg hard capsules
- Bedranol 80mg SR Capsules
- Bedranol 160mg SR Capsules
- Betim 10mg Tablets
- Carbo-Dome Cream
- Bisoprolol 2.5mg/5mg/10mg film coated tablet
- Phenergan Injection
- Rivotril 0.5 mg and 2 mgTablets
- Rivotril Ampoules
- RELPAX 20mg and 40mg Film-Coated Tablets
- Witch Doctor ® 81.5%w/w Gel
- Levetiracetam Actavis 1,000 mg film-coated tablets
- Levetiracetam Actavis 250 mg film-coated tablets
- Levetiracetam Actavis 500 mg film-coated tablets
- Levetiracetam Actavis 750 mg film-coated tablets
- Lidocaine Hydrochloride Injection BP 1% w/v plastic ampoules
- Lidocaine Hydrochloride Injection BP 2.0% w/v
- Omeprazole 10mg Capsules
- Omeprazole 20mg Capsules
- Panadol Extra Advance 500 mg/65 mg Tablets
- Allopurinol Tablets BP 300mg
- Allopurinol Tablets BP 100mg
- Anadin Ultra Double Strength 400mg Capsules/Anadin LiquiFast 400mg Capsules
- Calcipotriol Scalp Solution
- Bupivacaine Hydrochloride Injection BP 0.5% w/v.
- Lescol (fluvastatin* sodium) 20 mg and 40 mg capsules
- Meropenem 1 g Powder for Solution for Injection or Infusion
- VALTREX Tablets 250mg
- Vesicare 5mg & 10mg film-coated tablets
- Zomig 5mg Nasal Spray
- Water for Injections
- Tizanidine 2mg Tablets
- NovoRapid 100 U/ml in a vial, NovoRapid Penfill 100 U/ml, NovoRapid FlexPen 100 U/ml, NovoRapid FlexTouch 100 U/ml
- Orfadin 10 mg hard capsules
- Orfadin 2 mg hard capsules
- Natecal D3 Chewable Tablets
Soft Tissue Sarcoma
Please note - The EPG Soft Tissue Sarcoma Knowledge Centre is for Doctors and other Healthcare Professionals. Enter the Soft Tissue Sarcoma Knowledge Centre.
Soft Tissue Sarcomas (STS) are malignant (cancerous) tumors that develop in tissues which connect, support, or surround other structures and organs of the body. Muscles, tendons (bands of fiber that connect muscles to bones), fibrous tissues, fat, blood vessels, nerves, and synovial tissues are types of soft tissue.
Soft tissue sarcomas are grouped together because they share certain microscopic characteristics, have similar symptoms, and are generally treated in similar ways1. They are usually named for the type of tissue in which they begin.
Every year approximately 13,000 new cases of soft tissue sarcomas are diagnosed in adults and children in Europe. The 5-year survival rate for patients with soft tissue sarcoma is around 90% if the cancer is detected in early phases and before it has spread. However, the 5-year survival rate is 10% to 15% for sarcomas with metastasis.
Management of STS depends on the stage of disease and histological subtype2. Surgery is the mainstay of treatment for patients with localised disease and is often curative. However, as recurrence is likely to occur when tumour cells remain after surgery, adjuvant radiotherapy is often also considered, especially for patients with intermediate or high-grade tumours. Radiotherapy is also often administered for patients in whom surgery is inappropriate or who decline surgery.2
There are a number of Associations and Organisations across Europe who strive to inform others of this disease as well as offer help and support to those affected or to those who know and want to help those suffering.
Enter the Soft Tissue Sarcoma Knowledge Centre
What’s in the Soft Tissue Sarcoma Knowledge Centre?
- Home
- Soft Tissue Sarcoma
- Introduction
- Staging and Risk Assessment
- Chemotherapy
- Disease Progression
- Management - Overview
- Novel Therapy - Trabectedin - Clinical Studies
- Novel Therapy - Trabectedin - Clinical Updates
- Novel Therapy - Trabectedin - Efficacy
- Novel Therapy - Trabectedin - Mode of action
- Novel Therapy - Trabectedin - Research and Advances
- Novel Therapy - Trabectedin - Safety and Tolerability
- Novel Therapy - Trabectedin
- Radiotherapy
- Surgery
- Associations and Organisations
- Congresses
- Glossary
- Guidelines
- Research Groups
- Classification
- Clinical Presentation
- Epidemiology
- Types By Site
References:
1. Cormier JN, Pollock RE. Soft tissue sarcomas. CA: A Cancer Journal for Clinicians 2004; 54(2):94–109.
2. Clark MA, Fisher C et al. (2005) “Soft-tissue sarcomas in adults.” N Engl JMed 353(7): 701–11.
- YONDELIS Solution for Infusion.
Yondelis is indicated for the treatment of patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients. Yondelis in combination with pegylated ... - Vincristine (Generic)
... 3. Multiple myeloma. 4. Solid tumours, including breast carcinoma, small cell bronchogenic carcinoma, head and neck carcinoma and soft tissue sarcomas. 5. Paediatric solid tumours, including Ewing's sarcoma, embryonal rhabdomyosarcoma, neuroblastoma, Wilms' tumour, retinoblastoma and medulloblastoma ...
